Thales Reinforces Its eSIM Management Leadership With Google Cloud Certified and Energy Efficient Services
1.3.2023 10:00:00 EET | Business Wire | Press release
Thales, the world leader in eSIM management, supports the growth of eSIM-enabled consumer and industrial devices with Google Cloud expertise. Thales' pioneering Cloud solution combines its own security assets with Google's cloud presence in 200 countries to provide enhanced security, flexibility, and service availability to MNOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005040/en/
Thales, a global leader in eSIM management. @Thales
Remote eSIM activation, anytime and anywhere
By 2025, the number of eSIM connections is estimated to reach close to 9 billion1. Fuelled by 5G, the growth in connections is the result of increased connectivity of consumer products such as smartphones, tablets and wearables, and numerous industrial devices. With Thales’ eSIM management platform hosted on Google Cloud completed with Thales digital onboarding solutions, MNOs can offer their subscribers the speed, convenience and efficiency of activating subscriptions remotely. Today, Thales is able to meet high demands from hundreds of customers worldwide, including Telefonica, one of the world's largest telco operators and mobile network providers.
The perfect response to MNOs digital transformation and exponential IoT growth
With easy and secure access to Thales services hosted on Google Cloud, mobile operators can respond immediately to surging demand for eSIM activation and offer their subscribers a full digital experience. Such solutions also provide greater scalability as well as resources mutualisation, enabling mobile operators efficiently and rapidly deploy new services. In terms of security, Thales keeps full control, by designing highly secure end-to-end hardware and software, as well as by storing and managing the secret codes in its secure vaults (secret codes are keys used by devices for eSIM activation to securely access mobile networks). This underpins world-class data privacy, sovereign cloud approach and rigorous defence against cyberattacks.
Certified and sustainable
The eSIM usage has become mission-critical to enable a sustainable access to connectivity for the expanding consumer and industrial IoT. Thales’ integration of global GSMA-certified solution protects MNOs against interruptions in any part of the world. MNOs therefore benefit from outstanding disaster recovery, business continuity and improved quality of services.
Google Cloud’s is today one of the most energy efficient clouds2 in the industry and aims to operate entirely on carbon free energy 24/7 and everywhere in the world by 2030.
“ We have been trustfully partnering with Thales for years to address new connectivity challenges and MNO needs with cloud technology. This future-proof solution provides the market with the required flexibility, security, and resilience to meet consumer’s ‘anytime anywhere’ wish, while also addressing new technological requirements. Adding to Google Cloud services, the security aspect brought by Thales and its remote eSIM management leadership, brings relevance and support to MNOs eSIM strategy.” said Amol Phadke, General manager, Global Telecom Industry at Google Cloud
“There is an increasing consumers’ adoption of eSIM enabled phones, wearables and tablets while MNOs are ramping up for the 5G and IoT revolutions. Two years after the announcement of our partnership with Google Cloud, Thales’ pioneering Cloud eSIM solution has reached its full maturity. Our customers can trust us to support them in their eSIM strategy, meeting data privacy regulations as well as protecting them against the most sophisticated cyber threats” said Eva Rudin, VP Mobile Connectivity Solutions at Thales.
1
Counterpoint, eSIM Ecosystem CORE Analysis, May 2022
2
On average, a Google data center is twice as energy efficient as a typical enterprise data center.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations — connectivity, big data, artificial intelligence, cybersecurity and quantum computing — to build a future we can all trust, which is vital to the development of our societies.
The company provides solutions, services and products that help its customers —businesses, organisations and states — in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion
PLEASE VISIT
Thales Group
Digital Identity & Security
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005040/en/
Contact information
Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom